KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 112 filers reported holding KEROS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,108 | -17.7% | 11,233 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $435,310 | +9.8% | 10,834 | +16.7% | 0.00% | 0.0% |
| Q1 2023 | $396,555 | -9.3% | 9,287 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $437,078 | +36.2% | 9,102 | +6.6% | 0.00% | +50.0% |
| Q3 2022 | $321,000 | +47.9% | 8,542 | +8.7% | 0.00% | +100.0% |
| Q2 2022 | $217,000 | -48.5% | 7,858 | +1.4% | 0.00% | -50.0% |
| Q1 2022 | $421,000 | -13.2% | 7,748 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $485,000 | +43.5% | 8,293 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $338,000 | -8.9% | 8,541 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $371,000 | -22.1% | 8,744 | +13.1% | 0.00% | -50.0% |
| Q1 2021 | $476,000 | -11.0% | 7,731 | +2.0% | 0.00% | 0.0% |
| Q4 2020 | $535,000 | +232.3% | 7,581 | +82.0% | 0.00% | +100.0% |
| Q3 2020 | $161,000 | +0.6% | 4,165 | -2.3% | 0.00% | 0.0% |
| Q2 2020 | $160,000 | – | 4,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |